Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

NicOx commences phase IIa trial with treatment for Paget's disease

Dec. 20, 1999

Warner-Lambert files IND for oral calcitonin product for osteoporosis

Dec. 20, 1999

Roberts launches emergency contraceptive in Canada

Dec. 20, 1999

Inhibitors of CPT-I from Sigma-Tau useful for hyperglycemic states, cardiovascular disorders

Dec. 20, 1999

Excellent hypoglycemic and hypolipidemic effects reported for new Takeda compounds

Dec. 17, 1999

Novartis files NDA for extended-release formulation of fluvastatin

Dec. 16, 1999

Antidiabetic thiazolidinediones under study at Taiho

Dec. 16, 1999

More on PTPase inhibitors in development at AHP

Dec. 16, 1999

Orphan Europe launches treatment for rare metabolic disorder in U.K.

Dec. 15, 1999

Orally active piperidine compounds from Novo Nordisk selectively stimulate GH release

Dec. 15, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...